UBS Group Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its price objective cut by equities researchers at UBS Group from $104.00 to $90.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the medical technology company’s stock. UBS Group’s price target suggests a potential upside of 8.13% from the stock’s current price.

A number of other brokerages have also recently commented on MDT. JPMorgan Chase & Co. decreased their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Citigroup decreased their price target on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Needham & Company LLC restated a “buy” rating and issued a $120.00 price target on shares of Medtronic in a research report on Thursday, March 26th. Sanford C. Bernstein raised their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Finally, Daiwa Securities Group decreased their price target on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $108.55.

Medtronic Stock Performance

Shares of MDT traded up $1.23 during midday trading on Wednesday, reaching $83.23. 10,380,459 shares of the stock were exchanged, compared to its average volume of 8,470,754. Medtronic has a twelve month low of $79.93 and a twelve month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company has a market cap of $106.86 billion, a P/E ratio of 23.18, a PEG ratio of 2.21 and a beta of 0.75. The stock’s 50 day simple moving average is $90.80 and its 200 day simple moving average is $95.53.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter last year, the firm earned $1.38 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic will post 5.57 earnings per share for the current year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.26% of the company’s stock.

Institutional Trading of Medtronic

Several hedge funds and other institutional investors have recently made changes to their positions in MDT. Corundum Trust Company INC bought a new stake in shares of Medtronic during the third quarter worth about $27,000. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic during the fourth quarter worth about $27,000. Anfield Capital Management LLC grew its holdings in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Monetary Solutions Ltd acquired a new position in shares of Medtronic in the fourth quarter worth approximately $27,000. Finally, Valley Wealth Managers Inc. bought a new stake in Medtronic in the third quarter valued at approximately $29,000. 82.06% of the stock is currently owned by institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: First clinical uses reported for the Stealth AXiS Autopilot robotic platform — surgeons have begun using Medtronic’s Stealth AXiS in the U.S., marking an important commercialization milestone for its surgical robotics/navigation push; early adoption can support future procedure volume and competitive positioning. First surgeons use Medtronic Stealth AXiS Autopilot surgical robotic platform
• Positive Sentiment: Product integration with GE HealthCare for intraoperative ultrasound — Medtronic announced a digital integration between Stealth AXiS navigation and GE’s bkActiv ultrasound to deliver real‑time imaging for neurosurgery, strengthening the product’s utility and go‑to‑market appeal. Medtronic And GE HealthCare Tie Neurosurgical Imaging Upgrade To MDT Valuation
• Positive Sentiment: Medtronic leads $100M investment in Pulnovo Medical and struck a commercial agreement — this expands Medtronic’s exposure to pulmonary therapies and shows opportunistic venture investing to supplement organic pipeline growth. Medtronic leads $100M investment in Pulnovo Medical
• Neutral Sentiment: CathWorks acquisition closed for $585M — management expects the deal to be immaterial to FY2027 earnings and accretive in later years, making this a longer‑term strategic add rather than an immediate earnings lever. Medtronic concludes CathWorks’ acquisition for $585m
• Neutral Sentiment: Industry reports and product-market mentions (wearable injectors, MiniMed coverage) keep Medtronic visible across durable medtech categories — supportive for long-term optionality but not immediate catalysts. Wearable Injectors Market Report 2026
• Negative Sentiment: Share-price weakness and recent short-term declines — multiple finance articles highlight MDT’s recent underperformance (YTD and last month/week), which can weigh on sentiment and trigger technical selling. Is It Time To Reconsider Medtronic (MDT) After Recent Share Price Weakness?
• Negative Sentiment: Recent coverage noting a sharper intraday dip and commentary on analyst/market reactions — headlines calling out a more significant pullback than the broader market can amplify selling pressure. Medtronic (MDT) Sees a More Significant Dip Than Broader Market
• Neutral Sentiment: Competitive context — Intuitive Surgical’s strong quarter reminds investors that surgical-robotics outcomes and valuation responses can be mixed; competitive dynamics matter for investor expectations of Medtronic’s robotics ramp. Intuitive Surgical Earnings Show Big Beats Don’t Always Spark Stock Rallies

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).